Ambrx Biopharma Inc.
10975 North Torrey Pines Road
La Jolla, California 92037
VIA EDGAR
August 3, 2022
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Attn: | Tim Buchmiller |
| Re: | Ambrx Biopharma Inc. | |
| Registration Statement on Form F-3 (File No. 333-266404) | ||
| Request for Acceleration of Effective Date |
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Ambrx Biopharma Inc. (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-3 (File No. 333-266404) (the “Registration Statement”) to become effective on Friday, August 5, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact Carlos Ramirez of Cooley LLP at (858) 550-6157, or in his absence, Yoon-jee Kim of Cooley LLP at (212) 479-6792.
| Sincerely, | ||
| AMBRX BIOPHARMA INC. | ||
| By: | /s/ Sonja Nelson | |
| Sonja Nelson | ||
| Chief Financial Officer | ||
| cc: | Feng Tian, Ambrx Biopharma Inc. |
Carlos Ramirez, Cooley LLP
Yoon-jee Kim, Cooley LLP
